- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05272254
Povidone Iodine Efficacy Study (PIES)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
Primary:
To assess the efficacy of 10% PVPI in children with S-ECC to prevent new cavitated caries lesions that require follow-up restorative/surgical intervention after oral rehabilitation in the Operating Room (OR) under general anesthesia.
The primary outcome variable is time from randomization to relapse. The development of an ICDAS caries code 3 (cavitated caries lesion) or higher lesion post dental surgery is the sentinel event to calculate time to relapse.
Secondary:
To determine incidence and severity of dental caries following oral rehabilitation in the OR.
This outcome measure will be assessed by counting non-cavitated and cavitated carious lesions and any filled (due to caries), missing (due to caries) and sealed surfaces over the 2-year study period. The International Caries Diagnostic Assessment System (ICDAS) index will be used.
- To determine diversity and composition of oral microbiota, including cariogenic Streptococcus Mutans, Lactobacilli and Candida species over the 2-year study period.
16S rRNA amplicon analysis of saliva from all participants will be used to identify bacterial taxa associated with dental caries. We will also quantify Colony Forming Units per mL (CFU/mL) of S. mutans, Lactobacilli and Candida species.
3. To determine the frequency of adverse event occurrence. Adverse events (AEs) will be collected from the parent/primary caregiver, as well as those observed by study investigators including unanticipated problems (UPs) and severe adverse events (SAEs) over the 2 year study period.
Population: Healthy children with S-ECC 24 to 71 months of age and their parents/primary caregivers from Rochester NY and the surrounding area will be invited to participate in this study. Enrolled children will be patients of record in the Pediatric Dentistry Division of the Eastman Institute for Oral Health (EIOH), University of Rochester, who require treatment for S-ECC in the OR under general anesthesia.
Phase or Stage: Phase II RCT Number of Sites: 1 site, University of Rochester Description of Intervention: The test agent will be 10% PVPI (Betadine Solution, Purdue Frederick Co., Stamford, CT). The placebo will consist of fluoride-free sterile water for injection USP and commercial powdered tea without sweetener or lemon (Lipton decaffeinated unsweetened tea, Lipton, Unilever, Englewood Cliffs, NJ) with addition of Red and Yellow Food Color (McCormick and Co., Inc., Hunt Valley, MD) to simulate the color of the 10% PVPI.
After drying the teeth, up to 15 µl of 10% PVPI or placebo solution will be applied to the child's teeth with a microbrush. Following application of the test agent (PVPI or placebo), FV (Duraflor®- 5% Sodium Fluoride Varnish, Bubble gum flavor, AMD Medicom, Inc. Quebec, Canada) that is the standard of care will be applied with the manufacturer's supplied applicator.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Dorota T Kopycka-Kedzierawski, DDS, MPH
- Phone Number: 585-275-0706
- Email: Dorota_KopyckaKedzierawski@urmc.rochester.edu
Study Contact Backup
- Name: Kathy Bohn
- Phone Number: 585-273-5272
- Email: Kathy_Bohn@urmc.rochester.edu
Study Locations
-
-
New York
-
Rochester, New York, United States, 14620
- Recruiting
- University of Rochester
-
Contact:
- Kathy Bohn
- Phone Number: 585-273-5272
- Email: Kathy_Bohn@urmc.rochester.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provide signed and dated informed consent/permission form
- Parents/primary caregivers willing to comply with all study procedures and be available for the duration of the study
- Male or female, of any race, ethnicity, aged 24 to 71 months and their parents/primary caregivers who are 18 years of age or older or emancipated minors
- In good general health as evidenced by medical history, per PI, and in compliance with current CDC, NYS Department of Health and URMC COVID-19 guidelines. American Society of Anesthesiologists (ASA) categories will be used; children classified as ASA I and ASA II will be eligible for the study.
- Diagnosed with Severe-Early Childhood Caries (S-ECC) requiring treatment in the operating room (OR). A diagnosis of S-ECC will be based on the definition in accordance with American Academy of Pediatric Dentistry (AAPD)
Exclusion Criteria:
- Having a known allergy or sensitivity to iodine or seafood, red or yellow food coloring, or to tea, including a hypersensitivity to fluoride varnish, or having thyroid disease, as determined by medical history
- Receiving or having received treatment with another investigational drug within 30 days of the baseline visit (V1)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Povidone Iodine
10% povidone iodine + fluoride varnish
|
applied to children's teeth
Other Names:
|
Placebo Comparator: Placebo
Placebo (iced tea) + fluoride varnish
|
applied to children's teeth
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Caries lesion
Time Frame: Randomization to relapse, up to 24 months
|
The primary outcome variable is time from randomization to relapse.
The development of an ICDAS caries code 3 (cavitated caries lesion) or higher lesion post dental surgery is the sentinel event to calculate time to relapse.
|
Randomization to relapse, up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of dental caries
Time Frame: Randomization to relapse, up to 24 months
|
To determine incidence and severity of dental caries following oral rehabilitation in the OR.
|
Randomization to relapse, up to 24 months
|
Diversity of oral microbiota
Time Frame: Randomization to relapse, up to 24 months
|
To determine diversity of oral microbiota, including cariogenic Streptococcus Mutans, Lactobacilli and Candida species over the 2-year study period.
Concentration (CFU/ml) will be measured
|
Randomization to relapse, up to 24 months
|
Adverse Event Occurrence
Time Frame: Enrollment to 24 months
|
To determine the frequency of adverse event occurrence
|
Enrollment to 24 months
|
Composition of Microbiota
Time Frame: Randomization to relapse, up to 24 months
|
To determine composition of oral microbiota, including cariogenic Streptococcus Mutans, Lactobacilli and Candida species over the 2-year study period.
Presence of species (yes or no) will be measured
|
Randomization to relapse, up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dorota T Kopycka-Kedzierawski, DDS, MPH, University of Rochester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00007064
- 21-057-E (Other Identifier: Funder)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early Childhood Caries
-
University of Novi SadRecruitingEarly Childhood CariesSerbia
-
Alexandria UniversityScience, Technology & Innovation Funding Authority (STDF)Completed
-
Cairo UniversityUnknown
-
The University of Hong KongResearch Grants Council, Hong KongUnknownEarly Childhood CariesHong Kong
-
Cairo UniversityUnknown
-
Hospital Nossa Senhora da ConceicaoCompletedEarly Childhood CariesBrazil
-
Beijing Friendship HospitalRecruitingEarly Childhood CariesChina
-
Cairo UniversityNot yet recruiting
-
Hacettepe UniversityActive, not recruitingEarly Childhood CariesTurkey
-
King Abdullah University HospitalJordan University of Science and TechnologyCompleted
Clinical Trials on 10% povidone iodine + FV
-
Ikechukwu Bartholomew UlasiCompleted
-
Ain Shams UniversityRecruitingSurgical Wound Infection | Surgical Site InfectionEgypt
-
Ain Shams Maternity HospitalUnknownInfection; Cesarean SectionEgypt
-
Cairo UniversityRecruitingPostoperative Infection | Cesarean Section Complications | Vaginal InfectionEgypt
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Cadence PharmaceuticalsCompletedInfectionUnited States, Germany, France, Spain
-
S.K. Lerik General HospitalCompletedWounds and Injuries | Wound Heal | Laceration Face | Laceration Arm | Laceration of LegIndonesia
-
University of BirminghamChristian Medical College and Hospital, Ludhiana, India; Lagos State University and other collaboratorsUnknownAbdominal Surgery | Surgical Site InfectionNigeria
-
University of MinnesotaCompleted
-
DR. MALA KHANDhaka Medical CollegeCompleted